Bernstein Liebhard LLP is investigating whether the Board of Directors of ISTA Pharmaceuticals, Inc. (“ISTA” or the “Company”) (Nasdaq: ISTA) is breaching its fiduciary duty to its shareholders in failing to embrace premium offers for the company by Valeant Pharmaceuticals International, Inc. (“Valeant Pharmaceuticals”). As reported, ISTA shareholders would receive $6.50 in cash for each share they own. The investigation is focused on ISTA’s failing to embrace Valeant Pharmaceuticals’ offers. If you are interested in discussing your rights as an ISTA shareholder and/or have information relating to the matter, please contact U. Seth Ottensoser at (877) 779-1414 or Ottensoser@bernlieb.com. Bernstein Liebhard has pursued hundreds of securities, consumer and shareholder rights cases and recovered over $3 billion for its clients. It has been named to The National Law Journal’s “Plaintiffs’ Hot List” in each of the last eight years. Bernstein Liebhard LLP10 East 40th StreetNew York, New York 10016(877) 779-1414 www.bernlieb.com ATTORNEY ADVERTISING. © 2011 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Mary U. Hoover. Prior results do not guarantee or predict a similar outcome with respect to any future matter.